Intuitive Surgical, Inc.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
The most durable razor-and-blades moat in medical devices — once a hospital installs da Vinci and trains its surgeons, switching is a career-level commitment measured in years, not months.
Intuitive Surgical's moat is built on Installed Base Lock-In and Surgeon Muscle Memory:
- The Surgeon Training Moat: A surgeon who spends 2-5 years mastering the da Vinci console develops deeply ingrained psychomotor skills that do not transfer to a competing platform. Retraining on Medtronic's Hugo or J&J's Ottava is not a software migration — it is a manual dexterity re-education. Hospitals that switch face surgeon credentialing delays, OR scheduling disruption, and patient outcome uncertainty.
- Razor-and-Blades at Scale: Intuitive sells capital equipment (da Vinci systems) at relatively modest margins, then earns 80%+ gross margins on the single-use instruments and accessories that are consumed in every procedure. With 11,710 da Vinci systems in the installed base (June 30, 2026) generating an average of 400+ procedures per year, this creates a durable, inflation-resistant recurring revenue stream that grows automatically with procedure volume.
- Outcomes Data Network Effect: Over 14 million da Vinci procedures have generated the world's largest proprietary robotic surgery outcomes database. This data advantage enables faster FDA clearance for new indications, stronger clinical evidence for hospital purchasing committees, and continuous software improvement — a compounding moat that competitors entering the market today cannot replicate for a decade.
- da Vinci 5 Platform Refresh: Launched in 2024, da Vinci 5 introduces force feedback, 10,000x more computing power, and AI-assisted surgical guidance. The upgrade cycle refreshes switching cost lock-in for the existing installed base while expanding Intuitive's AI surgery leadership. Each new system sold today embeds Intuitive deeper into hospital infrastructure for the next 10-15 years.
Moat Verdict
AI is a net tailwind for Intuitive Surgical. Unlike software companies where AI threatens to commoditize the product, AI strengthens Intuitive's moat by adding guided surgery intelligence on top of the installed base — creating a new monetization layer without displacing the physical lock-in. The primary competitive risk is not AI but well-funded platform challengers (Medtronic, J&J) in the next 5-10 years.
84.3 resilient · 72.6 vulnerable · 80/20 = 81.9 · + 1 strength · = 83
Open a moat to read its note.
The da Vinci console is among the most deeply learned physical interfaces in professional practice: surgeon muscle memory, hand-eye recalibration and haptic intuition built over years of cases do not transfer to a rival platform. The habit is formed on 11,710 installed systems (June 30, 2026) each running 400+ procedures a year, and surgeons who move hospitals pull da Vinci purchases with them.
Robotic surgical workflow is embedded into hospital OR scheduling systems, credentialing databases, and procedure coding. Every step from patient consent to billing references Intuitive's platform — migrating is an operational disruption, not merely a software swap.
Intuitive does not control access to a public data source. The 14M+ procedure outcomes dataset is its own private data, already rated strong under proprietaryData; scoring it here as well counted one fact twice. Previously strong.
Surgical robotics R&D requires the intersection of mechanical engineering, control theory, medical imaging, and regulatory affairs expertise that is genuinely scarce. Intuitive's 30-year head start in recruiting and retaining this talent is a structural hiring moat.
Hardware, instruments and accessories, service, surgeon training and analytics come as one hospital relationship. The lock inside it is the per-procedure instrument revenue already rated strong under transaction embedding and the console habit rated strong under learned interfaces, so the bundle rates intact here (one fact, one pillar).
Real-world surgical outcomes data from 14M+ procedures feeds continuous software improvement, AI model training, and clinical evidence generation. No competitor can buy or replicate this dataset — it only grows with each procedure performed on the installed base.
Each new surgical indication requires a separate FDA 510(k) or De Novo clearance, and hospital credentialing committees tie surgeon privileges to specific approved platforms. Competitor platforms must earn their own clearances per indication — a 3-7 year regulatory lag per procedure type.
As more surgeons train on da Vinci, they create demand pull when they move between hospitals — new employers purchase da Vinci to retain recruited surgeons. The peer influence network within surgical specialties also drives adoption, with leading academic centers setting the standard.
Single-use instruments are consumed in every procedure and cannot be substituted mid-operation. Each surgical case generates $1,500-2,500 in consumable revenue that is physically inseparable from the procedure itself. This is as close to transaction-embedded revenue as medical devices get.
Not a system-of-record business: the primary record for surgical data is the hospital EMR (Epic, Cerner), and My Intuitive's procedure analytics and training data are a secondary data position rated under proprietaryData. A pillar that never applied is not applicable rather than weakened. Previously weakened.
Largest installed base spreads R&D and service costs and lowers instrument unit cost, but Medtronic and J&J can fund the same scale.
Buyers are enterprises choosing on switching cost, integration and performance, which the other pillars rate. The name carries reputation, not a price premium it could hold on brand alone.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
The most durable razor-and-blades moat in medical devices — once a hospital installs da Vinci and trains its surgeons, switching is a career-level commitment measured in years, not months.
Growth Score
No new earnings since the July 16 Q2 2026 beat: revenue $2.89B (+19% YoY), worldwide procedures +16% (da Vinci +15%, Ion +36%), non-GAAP EPS $2.80 (+28%) on a 42% non-GAAP operating margin, 468 da Vinci systems placed (246 dV5), installed base 11,710 (+12%). The print beat, but full-year da Vinci procedure guidance of 13.5–15.5% — below the 17–20% pace of FY2025 — signaled deceleration, with US procedure growth moderating to ~12% as benign categories are deferred. Shares fell to ~$345 on July 17 and bottomed near $332 on July 23; by August 6 they had recovered to ~$375 with no incremental fundamental print. Q3 results are the next catalyst. dV5 upgrade momentum and Ion still underwrite low-to-mid-teens growth, but the ~20% procedure-growth era is moderating.
Valuation Score
At ~$375 (August 6, 2026), ISRG has recovered ~9% from the July 17 post-print close of ~$345 and ~13% from the July 23 low of ~$332 — a partial bounce with no new earnings — but remains ~20% below the June ~$469 peak and ~10% below the $415 base case at a ~$132B market cap. Forward P/E has re-expanded to ~33× (NTM) from the ~31× July lows, still below the historical 40–55× band. Bear ($270) reflects sustained deceleration and share loss to Medtronic Hugo / J&J Ottava; base ($415) assumes 13–15% procedure growth with margins holding ~42%; the bounce narrows but does not close the margin of safety opened by the July de-rating. Street mean target (~$490) sits above our base.
The Surgical Flywheel
Intuitive Surgical's moat is built on Installed Base Lock-In and Surgeon Muscle Memory:
- The Surgeon Training Moat: A surgeon who spends 2-5 years mastering the da Vinci console develops deeply ingrained psychomotor skills that do not transfer to a competing platform. Retraining on Medtronic's Hugo or J&J's Ottava is not a software migration — it is a manual dexterity re-education. Hospitals that switch face surgeon credentialing delays, OR scheduling disruption, and patient outcome uncertainty.
- Razor-and-Blades at Scale: Intuitive sells capital equipment (da Vinci systems) at relatively modest margins, then earns 80%+ gross margins on the single-use instruments and accessories that are consumed in every procedure. With 11,710 da Vinci systems in the installed base (June 30, 2026) generating an average of 400+ procedures per year, this creates a durable, inflation-resistant recurring revenue stream that grows automatically with procedure volume.
- Outcomes Data Network Effect: Over 14 million da Vinci procedures have generated the world's largest proprietary robotic surgery outcomes database. This data advantage enables faster FDA clearance for new indications, stronger clinical evidence for hospital purchasing committees, and continuous software improvement — a compounding moat that competitors entering the market today cannot replicate for a decade.
- da Vinci 5 Platform Refresh: Launched in 2024, da Vinci 5 introduces force feedback, 10,000x more computing power, and AI-assisted surgical guidance. The upgrade cycle refreshes switching cost lock-in for the existing installed base while expanding Intuitive's AI surgery leadership. Each new system sold today embeds Intuitive deeper into hospital infrastructure for the next 10-15 years.
Moat Verdict
AI is a net tailwind for Intuitive Surgical. Unlike software companies where AI threatens to commoditize the product, AI strengthens Intuitive's moat by adding guided surgery intelligence on top of the installed base — creating a new monetization layer without displacing the physical lock-in. The primary competitive risk is not AI but well-funded platform challengers (Medtronic, J&J) in the next 5-10 years.
84.3 resilient · 72.6 vulnerable · 80/20 = 81.9 · + 1 strength · = 83
Open a moat to read its note.
The da Vinci console is among the most deeply learned physical interfaces in professional practice: surgeon muscle memory, hand-eye recalibration and haptic intuition built over years of cases do not transfer to a rival platform. The habit is formed on 11,710 installed systems (June 30, 2026) each running 400+ procedures a year, and surgeons who move hospitals pull da Vinci purchases with them.
Robotic surgical workflow is embedded into hospital OR scheduling systems, credentialing databases, and procedure coding. Every step from patient consent to billing references Intuitive's platform — migrating is an operational disruption, not merely a software swap.
Intuitive does not control access to a public data source. The 14M+ procedure outcomes dataset is its own private data, already rated strong under proprietaryData; scoring it here as well counted one fact twice. Previously strong.
Surgical robotics R&D requires the intersection of mechanical engineering, control theory, medical imaging, and regulatory affairs expertise that is genuinely scarce. Intuitive's 30-year head start in recruiting and retaining this talent is a structural hiring moat.
Hardware, instruments and accessories, service, surgeon training and analytics come as one hospital relationship. The lock inside it is the per-procedure instrument revenue already rated strong under transaction embedding and the console habit rated strong under learned interfaces, so the bundle rates intact here (one fact, one pillar).
Real-world surgical outcomes data from 14M+ procedures feeds continuous software improvement, AI model training, and clinical evidence generation. No competitor can buy or replicate this dataset — it only grows with each procedure performed on the installed base.
Each new surgical indication requires a separate FDA 510(k) or De Novo clearance, and hospital credentialing committees tie surgeon privileges to specific approved platforms. Competitor platforms must earn their own clearances per indication — a 3-7 year regulatory lag per procedure type.
As more surgeons train on da Vinci, they create demand pull when they move between hospitals — new employers purchase da Vinci to retain recruited surgeons. The peer influence network within surgical specialties also drives adoption, with leading academic centers setting the standard.
Single-use instruments are consumed in every procedure and cannot be substituted mid-operation. Each surgical case generates $1,500-2,500 in consumable revenue that is physically inseparable from the procedure itself. This is as close to transaction-embedded revenue as medical devices get.
Not a system-of-record business: the primary record for surgical data is the hospital EMR (Epic, Cerner), and My Intuitive's procedure analytics and training data are a secondary data position rated under proprietaryData. A pillar that never applied is not applicable rather than weakened. Previously weakened.
Largest installed base spreads R&D and service costs and lowers instrument unit cost, but Medtronic and J&J can fund the same scale.
Buyers are enterprises choosing on switching cost, integration and performance, which the other pillars rate. The name carries reputation, not a price premium it could hold on brand alone.
Growth Analysis
Growth Drivers
Key Risk
US benign-procedure deferrals persist and full-year procedure growth settles below 13.5%, or Medtronic Hugo (US urology cleared Dec 2025) and J&J Ottava take general-surgery share, compressing ISRG's premium multiple further through 2027.
Score Derivation
80.0 base − 1.3 trajectory + 4 margin − 5 risk = 78
Base 80 (15% blended CAGR from guided procedure deceleration and Street fade) + trajectory (−1.3: da Vinci decelerating, Ion and EPS stable) + margin expanding (+4) − competitive/deceleration risk moderate (−5) = 78
Price Scenarios (12–24 Months)
Valuation Multiples
| Trailing P/E (GAAP) | ~43× |
| Forward P/E (NTM) | ~33× |
| PEG Ratio | ~2.1× |
| Price / Sales (NTM) | ~10.6× |
| Price / FCF | ~41× |
Forward P/E ~33× remains below ISRG's historical 40–55× band after the July de-rating and partial August bounce — cheaper versus its own history, still rich versus the medtech median. PEG ~2.1× is full for mid-teens growth, so the multiple is not a bargain on growth alone. The trailing-to-forward gap (43×→33×) still reflects continued double-digit EPS growth rather than an earnings stumble.
Approximate figures as of August 2026.
Where We Are vs Targets
Loading live price…
Procedure deceleration deepens, competitive platforms take general-surgery share, and the premium multiple compresses toward the market as growth normalizes to double digits.
- US benign-procedure deferrals persist and full-year da Vinci procedure growth settles below 13.5% as elective volumes stay macro-sensitive
- Medtronic Hugo (US urology cleared Dec 2025) and J&J Ottava gain traction in general surgery, pressuring da Vinci ASPs and slowing placements
- dV5 gross-margin mix plus tariff exposure caps operating-margin expansion, and rising R&D spend compresses earnings leverage
- Forward multiple de-rates toward ~23× on 2027 EPS as the ~20% procedure-growth premium is repriced out
Procedure volume grows 13–15% through 2027 as the dV5 upgrade cycle continues and Ion scales, with non-GAAP operating margin holding near 42%.
- Full-year da Vinci procedure growth lands in the guided 13.5–15.5% range; international placements offset softer US benign volumes
- dV5 upgrade cycle sustains 1,700+ system placements annually, keeping the installed base compounding above 12%
- Ion procedures continue mid-30s% growth, establishing interventional pulmonology as a durable second vector
- Non-GAAP EPS reaches ~$11.70 in 2027 at a ~35× forward multiple as the multiple partially recovers from the July lows
Procedure growth reaccelerates as benign deferrals reverse, dV5 AI-guided surgery gains clinical traction, and the premium multiple re-rates back toward its historical band.
- US elective volumes recover and worldwide procedure growth reaccelerates toward 17%+ as deferred benign cases return
- AI-assisted guidance on da Vinci 5 gains FDA clearance as a clinical decision-support layer, adding a SaaS-like revenue stream on top of instruments
- Ion captures a growing share of the lung-biopsy market, contributing $1B+ in high-margin recurring revenue
- Forward multiple re-rates back toward ~48× on 2027 EPS as double-digit-plus growth durability is re-established